amifampridine has been researched along with Anoxemia in 3 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peterson, C | 2 |
| Gibson, GE | 3 |
| Freeman, GB | 1 |
| Mykytyn, V | 1 |
3 other studies available for amifampridine and Anoxemia
| Article | Year |
|---|---|
3,4-diaminopyridine alters acetylcholine metabolism and behavior during hypoxia.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Behavior, Animal; Brain; Cal | 1982 |
Synaptosomal calcium metabolism during hypoxia and 3,4-diaminopyridine treatment.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Hypoxia; Male; Mice; Synaptosomes | 1984 |
Differential alteration of dopamine, acetylcholine, and glutamate release during anoxia and/or 3,4-diaminopyridine treatment.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Calcium; Corpus Striatum; Do | 1987 |